Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...